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Background: To determine whether the effect of androgen deprivation therapy (ADT) on the risk of biochemical
failure varies at different doses of radiation in patients treated with definitive external beam radiation for
intermediate risk prostate cancer (IRPC).
Methods: This study included 1218 IRPC patients treated with definitive external beam radiation therapy to the
prostate and seminal vesicles from June 1987 to January 2009 at our institution. Patient, treatment, and tumor
information was collected, including age, race, Gleason score, radiation dose, PSA, T-stage, and months on ADT.
Results: The median follow-up was 6 years. A total of 421(34.6%) patients received ADT, 211 (17.3%) patients
experienced a biochemical failure, and 38 (3.1%) developed distant metastasis. On univariable analyses, higher
PSA, earlier year of diagnosis, higher T-stage, lower doses of radiation, and the lack of ADT were associated
with an increased risk of biochemical failure. No difference in biochemical failure was seen among different
racial groups or with the use of greater than 6 months of ADT compared with less than 6 months. On multivariate
analysis, the use of ADT was associated with a lower risk of biochemical failure than no ADT (HR, 0.599; 95% CI,
0.367-0.978; P < 0.04) and lower risk of distant metastasis (HR, 0.114; 95% CI, 0.014-0.905; P = 0.04).
Conclusions: ADT reduced the risk of biochemical failure and distant metastasis in both low- and high dose
radiation groups among men with intermediate-risk PCa. Increasing the duration of ADT beyond 6 months
did not reduce the risk of biochemical failures. Better understanding the benefit of ADT in the era of dose
escalation will require a randomized clinical trial.
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The addition of Androgen Deprivation Therapy (ADT)
to radiation therapy for locally advanced prostate cancer
has demonstrated an improvement in local control and
overall survival benefit in a number of randomized con-
trolled trials [1-6]. Many of these trials were conducted
in an era where lower doses of radiation were used and
when patients were not evaluated in the risk groups that
are now used to make clinical decisions. In all of the* Correspondence: Michelle.Ludwig@bcm.edu
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external beam radiation, a dose of 70 Gy or less was used.
In 2002, results from a randomized trial by Pollack et al.,
showed that a 78 Gy dose improved survival and other
several similar dose-escalation studies changed the recom-
mended practice patterns by increasing the dose of pros-
tate radiation [7-10]. In the face of this new standard of
higher radiation doses, there is a need to evaluate the
benefit of adding ADT in terms of optimal patient selec-
tion and optimal timing and duration of ADT.
ADT can cause adverse physical and psychological side
effects in patients, such as decrease in muscle mass, in-
crease in diabetes, decrease in bone density, depression,rticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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anced between benefit and risk [11,12]. Current National
Comprehensive Cancer Network (NCCN) guidelines re-
flect this uncertainty by recommending “consideration of
4-6 months of ADT” if radiation therapy is given as defini-
tive treatment for intermediate and high risk prostate can-
cer [13]. Given the adverse physical and quality of life
effects of ADT and the unknown benefit of ADT in the
era of radiation dose escalation, an evaluation of its benefit
is needed. We conducted a retrospective clinical review of
prostate cancer patients to determine whether the effect
of ADT on the risk of biochemical failure and distant me-
tastasis was the same at different doses of radiation in
intermediate risk prostate cancer and whether the dur-
ation or timing of ADT resulted in improved outcomes.
Methods
Patient selection and pretreatment evaluation
This study included intermediate risk prostate cancer
(defined according to NCCN criteria) patients who were
treated at our institution with definitive external beam
radiation therapy from June 1987 to January 2009 [13].
The proposal approval was granted by the University of
Texas Health Science Center at Houston Committee for
The Protection of Human Subjects #HSC-SPH-12-0475.
The data were collected under the MD Anderson Cancer
Center IRB as Protocol RCR02-127. All patients had biopsy-
proven adenocarcinoma of the prostate with no metastatic
disease at the time of diagnosis. The initial evaluation con-
sisted of a history and physical, digital rectal exam to
evaluate tumor stage (based on the 1992 American Joint
Committee on Cancer staging system), serum PSA meas-
urement, and biopsy with Gleason histologic grading. The
bone scans and pelvic computerized tomography for sta-
ging were performed if the patient’s pretreatment PSA
was ≥10 or Gleason score was ≥8.
Treatment
All patients were treated with definitive external beam
radiation therapy to the prostateand seminal vesicles.
Prior to 2000, conventional four-field techniques were
used with doses prescribed to the isocenter. After 2000,
intensity-modulated radiation therapy was used to treat
the prostate and seminal vesicles. Lymph nodes were not
included in the clinical target volume. Radiation pre-
scription doses ranged from 60 to 78 Gy, depending on
the year of treatment. ADT was delivered either as total
androgen blockade or a lutenizing hormone releasing
hormone (LHRH) agonist alone, given at the discretion
of the treating radiation oncologist.
Follow-up and endpoints
Follow-up evaluation consisted of digital rectal examin-
ation and serum PSA measurements every 3-6 monthsfor the first two years, then every six months for the
next 3 years, and then annually after five years. Their
medical records were analyzed in a retrospective fashion
and institutional approval was received prior to initiating
the study. The biochemical failures were coded by the
“Phoenix” definition, or a rise in ≥2 ng/mL above the
lowest PSA achieved after treatment, with the actual
date of failure coded as the date of the PSA test [14]. Pa-
tients lost to follow-up were censored at the last visit.
The interval to biochemical failure was calculated from
the completion date of radiation therapy. Metastatic fail-
ures were outside of the pelvis, in nonregional lymph
nodes, bone, or other places. Coding of metastatic dis-
ease was based on chart review.
Statistical analysis
Descriptive measures were calculated for all variables,
and the patients were divided into ADT and no ADT
groups. Univariable analyses were conducted to deter-
mine the relationship between all variables and the out-
come of biochemical failure or distant metastasis, using
Cox proportional hazards models. Comparisons between
the use of ADT and the other variables were assessed
using a t-test. All variables were analyzed as continuous
variables except for radiation dose, which was consid-
ered a binary variable (low dose radiation was defined as
receiving < = 70 Gy, and high dose radiation was defined
as > 70 Gy) and ADT (yes or no) and timing of ADT
(neoadjuvant or adjuvant). Five and ten year rates of bio-
chemical failure were calculated for the overall and four
major groups. Radiation dose was evaluated for effect
modification by both addition of an interaction term in
the models and by stratification by dose of radiation.
After stratification, the log-rank test for homogeneity of
survival curves was used to test the difference in effect
of ADT among the two strata. Multivariable Cox propor-
tional hazards models were constructed to include pos-
sible confounders and effect modifiers when appropriate,
and variables were removed from the model one by one
to evaluate the change in hazards of the main effect vari-
ables. If a significant change was noted in the main out-
come variable being tested (about 10-20%), the variable
being tested remained in the model as a confounder.
The proportional hazards assumption was tested for
each variable in the model.
In the absence of definitive guidelines for placing pa-
tients on ADT, the decision is left to the treating phys-
ician. As such, this decision is likely to be influenced by
patient factors (e.g., age and comorbidity) and tumor fac-
tors (PSA, t-stage, Gleason score), which are all known to
contribute to outcomes of biochemical, local, and distant
failures. In order to address this selection bias, propensity
score analysis was utilized16. In our application, the pro-
pensity score estimates the conditional probability of a
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iates. To create the scores, a logistic model was used to es-
timate the probability of receiving ADT. Gleason Score,
age, year of diagnosis, T stage, and pretreatment PSA were
included into the multivariable logistic regression model,
as these factors had been decided a priori to affect a clini-
cian’s decision to place a patient on ADT, and variable
selection was conducted using a backwards stepwise
procedure. The propensity score-adjusted result has been
shown to remove 90% of the bias in a continuous distribu-
tion [15]. Matching on the propensity score and using the
propensity score as a covariate in the Cox model were
used for the outcome of biochemical failures. Matching
was then conducted; a 1:1 matched pair design without re-
placement was used to account for the nonrandom treat-
ment allocation. Case patients (with ADT) were matched
with control patients (no ADT). Since matching results inTable 1 Distribution of baseline variables by concurrent ADT
Variable ADT No ADT
(cases) (unmatched controls
n = 421 n = 797
Mean age 68.63 68.5
Mean PSA 8.47 8.18
Gleason Score (mean) 6.9 6.38
Race
White 278 (11.7%) 650 (81.6)
Black 79 (18.8%) 96 (12%)
Hispanic 44 (10.4%) 34 (4.3%)
Other 20 (4.8%) 17 (2.1%)
Year of diagnosis (mean) 2003 1997
Dose of radiation
Low≤ 70 28 (6.6%) 390 (49.8%)
High > 70 393 (93.3%) 407 (51.1%)
Clinical T-stage
T1 205 (48.7%) 336 (42.2%)
T2a 94 (22.3%) 164 (20.1%)
T2b,c 122 (30%) 267 (33.5%)
Length of concurrent hormones*
Short (≤6 months) 271 (64.4%)




Salvage 8 (1.9%) 114 (14.3%)
Radiation type<
3-D conformal 73 (17.3%) 546 (68.5%)
IMRT 348 (82.7%) 251 (31.5%)
*(of patients who received adjuvant hormones).
Percentages may not sum to 100% due to rounding.a violation of the independence assumption for a Cox
model, a frailty term was used for the matched pairs in
creation of the model.
Results and discussion
A total of 1218 patients with intermediate risk prostate
cancer were included in our study. Table 1 shows the
characteristics of the patients by ADT status. The mean
age for all patients was 68.5 years. Median follow up was
6 years. A total of 421 (34.6) patients received adjuvant
ADT, with 211 (17.3%) patients experiencing a biochem-
ical failure, and (3.1%) experiencing distant metastasis.
Five year rates of biochemical failure were 9.7% and ten
year rates were 16.1%. Of the patients who received
ADT, a total of 271 (64.4%) patients received 6 months
or less, and 150 (35.6%) patients were on ADT for longer
than 6 months. Radiation dose was divided into lowstatus
Total p-value no ADT p-value
) (unmatched) (matched controls) (matched)





















122 <0.001 40 (9.5%) <0.001
<0.001
619 <0.001 171 (40.6%)
599 250 (59.4%)
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for all analyses. A majority (76%) of the patients were
white. A total of 114 (14.3%) of patients who did not re-
ceive concurrent ADT subsequently were placed on sal-
vage hormonal therapy for failures compared to 8 patients
(1.9%) who initially received concurrent ADT.
As expected, there were significant differences in base-
line characteristics between the unmatched groups that
received ADT and those that did not receive ADT. No dif-
ference was noted in age, PSA, or T-stage, but patients
who did not receive ADT had lower mean Gleason scores,
earlier years of diagnosis, lower doses of radiation, more
biochemical and distant failures. About half (51%) were
treated with 3D conformal radiation, but the type of radi-
ation received was found to be highly correlated with radi-
ation dose, as 598 of the 599 patients who were treated
with IMRT were also given high dose radiation. As such,
radiation technique was not evaluated as a variable for the
remainder of the analyses.
When comparing the cohort of men who received
ADT to the matched controls (Table 1), no difference
was noted in age, PSA, Gleason score, or T-stage, but
patients who did not receive ADT had earlier years of
diagnosis (P <0.001), lower doses of radiation, more bio-
chemical and distant failures, were more likely to be
white, and were more likely to be placed on salvage hor-
mone therapy than patients who received ADT (P <0.001).
Matching appeared to resolve the difference in Gleason
score that was seen in the unmatched dataset.
On comparing the five and ten year rates of PSA fail-
ure by ADT status and radiation dose (Table 2), there is
a significant difference in the groups (P <0.001 for both
five and ten year failures).
On univariable analyses for biochemical failure, higher
PSA (HR, 1.075; 95% CI, 1.045- 1.106; P = <0.001), lower
Gleason Score (HR, 0.863; 95% CI, 0.761-0.978; P = <0.021),
earlier year of diagnosis (HR, 0.902; 95% CI, 0.875-0.930;
P <0.001), higher T-stage (HR, 1.215; 95% CI, 1.043-
1.416; P =0.012), lower doses of radiation (HR, 0.431; 95%
CI, 0.320-0.581; P <0.001), and no ADT (HR, 0.422; 95%
CI, 0.274-0.651; P <0.001) were associated with an in-
creased risk of biochemical failure (Table 3). No differenceTable 2 Univariable analysis of dose by ADT status
ADT status
Radiation dose ADT No ADT p-values*
High (>70)
Five year failure 4.10% 8.60%
Ten year failure 5.60% 11.10%
Low≤ 70)
Five year failure 3.60% 16.90%
Ten year failure 7.10% 32.60%
*p < 0.001 for both five and ten year failures.in biochemical failure was seen among different racial
groups, neoadjuvant hormone use (HR, 1.514; 95% CI,
0.444-5.160; p = 0.507) or with the use of greater than
6 months of ADT compared with less than 6 months (HR,
0.571; 95% CI, 0.23-1.416; P =0.226).
Univariable analysis for distant metastasis (Table 3)
showed that earlier year of diagnosis (HR, 0.926; 95% CI,
0.858-0.999; P =0.046), higher T-stage (HR, 1.668; 95%
CI, 1.125-2.474; P =0.011), and the lack of ADT (HR,
0.119; 95% CI, 0.016-0.882; P =0.037) were associated
with an increased risk of distant metastasis. No differ-
ence in distant failure (Table 3) was seen with age (HR,
1.016, 95% CI, 0.968-1.067; P =0.522), Pre-treatment
PSA (HR, 1.043; 95% CI, 0.975-1.115; P =0.22), Gleason
score (HR, 1.1; 95% CI, 0.796-1.519; P =0.564), race (HR,
0.678; 95% CI, 0.318-1.444; P =0.263) or with the use of
greater than 6 months of ADT compared with less than
6 months (HR, 1.00; 95% CI, 0.914-1.094; P =0.997). The
length of ADT and race were not statistically significant.
A Cox model for biochemical failure was constructed
and shown as the “Initial Cox” column in Table 3. Vari-
ables that were significant in the univariable analyses
were selected for inclusion in this model. The adjusted
model showed that higher pre-treatment PSA (HR,
1.079; 95% CI, 1.042-1.111; P <0.001), higher Gleason
Score (HR, 1.118; 95% CI, 1.012-1.393; P =0.026), earlier
year of diagnosis (HR, 0.923; 95% CI, 0.875-1.373; P =
0.004), higher T-stage (HR, 1.668; 95% CI, 1.125-2.474; P =
0.011), and the lack of ADT (HR, 0.599; 95% CI, 0.364-
0.978; P =0.04) were associated with an increased risk of
biochemical failure while controlling for these and the add-
itional variables included in the model (age, T-stage, and
radiation dose). The use of ADT was associated with a
lower risk of biochemical failure as compared to that of no
ADT (HR, 0.599; 95% CI, 0.367-0.978; P <0.04). An inter-
action term of adjuvant hormone use and radiation dose
was not significant when added to the model (HR, 3.883;
95% CI, 0.873- 17.26; P =0.075), meaning that radiation
dose is not an effect modifier. A subsequent multivariate
Cox proportional hazard model was performed after
matching (Table 4, column titled “Matched Cox Analysis”).
A Cox model for distant metastasis was constructed
and shown as the “Initial Cox” column in Table 4. Vari-
ables that were significant in the univariable analyses
were selected for inclusion in this model. The initial Cox
model showed that higher pre-treatment PSA (HR,
1.077; 95% CI, 1.004-1.155; P =0.039), higher Gleason
Score (HR, 1.480; 95% CI, 1.020-2.149; P =0.039), higher
T-stage (HR, 1.820; 95% CI, 1.201-2.759; P =0.005), and
the lack of ADT (HR, 0.114; 95% CI, 0.014-0.905; P =0.04)
were associated with an increased risk of distant metasta-
sis while controlling for these and the additional variables
included in the model, such as Age, year of diagnosis, and
radiation dose. The main outcome from the initial Cox,
Table 3 Univariable analysis of association with biochemical failure and distant metastasis
Biochemical failure Distant metastasis
Variable Hazard 95% CI p-value Hazard 95% CI p-value
Ratio Ratio
Age 1.000 0.980-1.02 0.983 1.016 0.968-1.067 0.522
Pre-treatment PSA 1.075 1.045-1.106 <0.001 1.043 0.975-1.115 0.22
Gleason Score 0.863 0.761-0.978 0.021 1.100 0.796-1.519 0.564
Year of Diagnosis 0.902 0.875-0.930 <0.001 0.926 0.858-0.999 0.046
T-stage 1.215 1.043-1.416 0.012 1.668 1.125-2.474 0.011
Radiation Dose (high vs low) 0.431 0.320-0.581 <0.001 0.593 0.287-1.226 0.158
ADT use (yes vs no) 0.422 0.274-0.651 <0.001 0.119 0.016-0.882 0.037
Length of Hormone use 0.981 0.938-1.026 0.403 1.000 0.914-1.094 0.997
Race 0.795 0.611-1.034 0.087 0.678 0.318-1.444 0.263
ADT Timing (Neoadjuvant vs adjuvant) 1.514 0.444-5.160 0.507 1.047 0.408-2.688 0.924
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risk of distant metastasis than no ADT. The effect of the
main variable, ADT use in both the initial and matched
Cox models were that the use of ADT was associated with
decreased risk of biochemical failure (HR, 0.599; 95% CI,
0.364-0.978; P = 0.04 for the initial Cox, (HR, 0.487; 95%
CI 0.228-0.822, P = 0.007 for the stratified Cox).
In addition, two other techniques with the propensity
score (stratification by propensity score and using the
propensity score as a covariate) were used as a sensitivity
analysis to validate these results [16]. The quintiles of
the propensity scores were used to stratify patients into
five homogeneous groups with respect to their likelihood
of being given ADT (the propensity score). A stratified
Cox regression analysis based on the propensity score
was then conducted with separate estimates for all of the
variables in each of the five strata. A weighted average of
the stratum-specific estimates was then calculated
(Table 5, “stratified Cox column”).Table 4 Cox models for biochemical failure and distant metas
Biochemical failure
Initial cox
Variable Hazard 95% CI p-value
Ratio
Age 1.003 0.983-1.024 0.76
Pre-treatment PSA 1.079 1.042-1.111 <0.001
Gleason Score 1.118 1.021-1.393 0.026
Year of diagnosis 0.923 0.875-9.74 0.004
T-stage 1.164 0.987-1.373 0.072
Radiation dose (high vs low) 0.864 0.572-1.306 0.489
Adjuvant Hormone use (yes vs no) 0.599 0.364-0.978 0.04
Interaction term ADT x XRT 3.883 0.873-17.26 0.075Stratifying the patients into propensity score quintiles
resulted in an improved balancing of patient characteris-
tics between the ADT/no ADT groups compared to the
initial differences prior to stratification seen in Table 1.
After stratification, the only significant differences
remaining within the ADT/no ADT groups after dividing
into propensity score quintiles were the year of diagnosis
in Quintile 2 and 3 (p = 0.013 and <0.001), the T-stage in
quintiles 2 (P = 0.032), 3 (p = 0.01) and 5 (p < 0.001), the
radiation dose in quintile 3 (p = 0.019), and the number
of failures in quintile 2 (p = 0.034) and 3 (p = 0.016). Fi-
nally, a Cox multivariable analysis for the outcome of bio-
chemical failure was conducted within each propensity
score quintile and the weighted average was calculated
and presented in Table 3. Due to the small number of
distant metastasis, a stratified analysis was not done
for that outcome. Finally, a Cox model was run which
included the propensity score as a covariate (Table 6, col-
umn “Cox with PS as Covariate”).tasis
Distant metastasis
Matched cox analysis Initial cox
Hazard 95% CI p-value Hazard 95% CI p-value
Ratio
0.983 0.955-1.011 0.235 1.022 0.972-1.074 0.393
1.055 0.997-1.116 0.062 1.077 1.004-1.155 0.039
1.996 1.045-3.812 0.036 1.480 1.020-2.149 0.039
0.992 0.907-1.085 0.867 0.969 0.856-1.098 0.623
1.371 1.058-1.774 0.017 1.820 1.201-2.759 0.005
0.928 0.490-1.757 0.818 1.039 0.413-2.609 0.936
0.487 0.288-0.822 0.007 0.114 0.014-0.905 0.04
Table 5 Cox models for biochemical failure: initial, stratified, PS as covariate
Initial cox Stratified by PS quintiles Cox with PS as covariate
Variable Hazard 95% CI p-value Hazard 95% CI p-value Hazard 95% CI p-value
Ratio Ratio
Age 1.003 0.983-1.024 0.76 1.005 0.984-1.026 0.666 1.004 0.984-1.025 0.684
Pre-treatment PSA 1.079 1.042-1.111 <0.001 1.065 1.026-1.105 0.001 1.056 1.020-1.093 0.002
Gleason Score 1.118 1.021-1.393 0.026 1.187 0.997-1.414 0.054 1.13 0.968-1.319 0.122
Year of diagnosis 0.923 0.875-9.74 0.004 0.888 0.821-0.961 0.003 0.875 0.816-0.941 <0.001
T-stage 1.164 0.987-1.373 0.072 1.09 0.899-1.323 0.379 1.053 0.873-1.272 0.588
Radiation dose (high vs low) 0.864 0.572-1.306 0.489 0.835 0.541-1.290 0.417 0.845 0.552-1.272 0.44
Adjuvant hormone use (yes vs no) 0.599 0.364-0.978 0.04 0.483 0.287-0.813 0.006 0.492 0.292-0.829 0.008
Propensity Score 4.679 1.172-18.682 0.029
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models (in addition to the matched analysis shown in
Table 3 of the paper) was that the use of ADT decreases
the risk of biochemical failure (HR, 0.599; 95% CI, 0.364-
0.978; P = 0.04 for the initial Cox, HR, 0.483; 95% CI,
0.287-0.813; P = 0.006 for the stratified Cox, and HR,
0.492; 95% CI, 0.292-0.829; P = 0.008 for the model with
propensity scores as a covariate). This study showed that
all three of the adjusted models showed a similar result as
the unadjusted Cox model; there is a significant benefit to
the use of adjuvant hormone therapy in reducing bio-
chemical failures.
A Cox model for distant failure was constructed and
shown as the “Initial Cox” column in Table 2. Variables
that were significant in the univariable analyses were se-
lected for inclusion in this model. The initial Cox model
showed that higher pre-treatment PSA (HR, 1.077; 95%
CI, 1.004-1.155; P = 0.039), higher Gleason Score (HR,
1.48; 95% CI, 1.020-2.149; P = 0.039), higher T-stage
(HR, 1.82; 95% CI, 1.201-2.759; P = 0.005), and the lack
of ADT (HR, 0.114; 95% CI, 0.014-0.905; P = 0.04) were
associated with an increased risk of biochemical failure
while controlling for these and the additional variablesTable 6 Cox models for distant metastasis: initial, PS as covar
Initial cox
Variable Hazard 95% CI
Ratio
Age 1.022 0.972-1.074
Pre-treatment PSA 1.077 1.004-1.155
Gleason Score 1.48 1.020-2.149
Year of diagnosis 0.969 0.856-1.098
T-stage 1.82 1.201-2.759
Radiation dose (high vs low) 1.039 0.413-2.609
Adjuvant hormone use (yes vs no) 0.114 0.014-0.905
Propensity Scoreincluded in the model, such as Age, year of diagnosis,
and radiation dose. The main outcome from the initial
Cox, shows that the use of ADT was associated with a
lower risk of distant failure than no ADT.
Due to the small number of distant failures, a matched
and stratified analysis was not done for this outcome,
but a Cox model was run which included the propensity
score as a covariate (Table 5, column “Cox with PS as
Covariate”). The effect of the main variable, ADT use in
all Cox models was that the use of ADT decreases the
risk of distant failure (HR, 0.114; 95% CI, 0.014-0.905;
P = 0.04 for the initial Cox, and HR, 0.16; 95% CI,
0.014-0.985; P = 0.048 for the model with PS as a covari-
ate). Both of the models showed a similar result; there is a
significant benefit to the use of adjuvant hormone therapy
in reducing distant failures.
Conclusions
Our study showed that the addition of ADT to external
beam radiation was associated with a significantly in-
creased PSA-free survival in intermediate risk patients.
This benefit held when controlling for other known prog-
nostic factors (age, PSA, Gleason score, year of diagnosis,iate
Cox with PS as covariate
p-value Hazard 95% CI p-value
Ratio
0.393 1.022 0.972-1.074 0.395
0.039 1.078 0.986-1.179 0.098
0.039 1.488 0.994-2.225 0.05
0.623 0.973 0.815-1.163 0.765
0.005 1.833 1.151-2.917 0.011
0.936 1.038 0.414-2.604 0.936
0.04 0.116 0.014-0.985 0.048
0.889 0.023-34.367 0.95
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propensity scores. However, our study did not show a
benefit to giving longer than 6 months of ADT.
Several trials have been conducted to evaluate the bene-
fits of combining radiation and ADT in intermediate risk
patients. In the RTOG 86-10 study, Pilepich et al. evalu-
ated 471 patients from 1987 to 1991 with clinical stage
T2-T4 with or without lymph node metastasis and ran-
domized them to radiation therapy (65-70 Gy) alone ver-
sus radiation therapy with hormone therapy (goserelin
and flutamide) for two months before and during radi-
ation therapy [2,17]. At 10 years of follow up, the com-
bined group showed an overall survival of 43% compared
with the radiation therapy only arm of 34%, which was
not statistically significant. However, statistically signifi-
cant improvements in disease-specific mortality (23% vs
36%, P = 0.01), distant metastasis (35% vs 47%, P = 0.006),
and biochemical failure (65% vs 80%, P <0.001) were
seen on the hormone therapy arm. D’Amico et al. evalu-
ated intermediate and high risk patients who received
70 Gy +/- 6 months of ADT and found that ADT re-
sulted in an improvement in overall survival (74% vs 61%,
P = 0.01) [15].
Once the benefit of adding hormone therapy to radi-
ation therapy was established, researchers began to in-
vestigate the optimum duration of hormone therapy by
shortening the regimens and comparing to more pro-
tracted regimens, and as in our study, found no benefit
to giving longer courses of ADT. The Irish Clinical
Oncology Research Group 97-01 study was conducted
from 1997 to 2001 [18]. This study randomized 261 pa-
tients with localized, node negative, intermediate to high
risk, PSA > 20 disease to 70 Gy of radiation with either a
short (4 month) or long (8 month) course of neoadjuvant
hormone therapy (LHRH with flutamide). At 102 months
of follow-up, there was no statistically significant differ-
ence between the two groups in terms of overall survival,
biochemical-free survival, or cancer-specific survival. The
Canadian Multicenter study was conducted from 1995 to
2001 [19]. A total of 378 men with clinically localized
cT1-T4 (43% intermediate risk) were randomized to re-
ceive either 3 or 8 months of hormone therapy (flutamide
and goserelin) prior to definitive radiation to 66 Gy. Over-
all, no difference was seen in biochemical failure or pat-
terns of failure between both arms in intermediate risk
patients. D’Amico et al. analyzed a total of 311 men with a
median age of 70, who had been enrolled on 3 prospective
randomized trials from 1987-2000 who received either
6 months or 3 years of hormone therapy in addition to
definitive radiation therapy [15]. Radiation doses were be-
tween 66 and 70 Gy and hormone therapy was given ei-
ther as combined androgen blockade and or from single-
agent therapy only. They found that after adjusting for
known prognostic factors, the use of 3 years of hormonetherapy did not improve survival compared to 6 months
of hormone therapy.
No trials have yet been completed which incorporate
higher doses of radiation and the current risk classifica-
tion as per NCCN guidelines. The current trial, RTOG
99-10, does use modern risk stratification schemes, com-
paring 8 weeks versus 28 weeks of neoadjuvant andro-
gen suppression followed by a 70 Gy dose of radiation
with 8 weeks of concurrent ADT and closed for accrual
in May of 2004. The preliminary results, presented in
abstract form, suggest no improvement of the endpoints
of biochemical, loco-regional, or distant relapse or death
with extending the neoadjuvant androgen suppression
[20]. A retrospective study focusing on patients treated
in the modern era (1993-2008) was conducted at our
own institution, and found that in unfavorable patients
(defined as Gleason 4 + 3 or T2c), the addition of ADT
provided an improvement in freedom from failure (74%
with no ADT vs 94% with ADT at 5 years, P = 0.0049)
[21]. The GETUG 14 randomized trial evaluated high
dose radiotherapy of 80 Gy alone or in combination with
4 months of ADT, and was closed prematurely due to
slow accrual, but intermediary analysis did not reach a
statistical significance [22,23].
Based on our findings, it appears that it is reasonable
to consider 4-6 months of ADT for intermediate risk pa-
tients. Since intermediate risk prostate cancer is a het-
erogeneous group, it is also reasonable to consider the
disease burden and comorbidities to assist in making the
clinical decisions regarding ADT in view of the higher
doses currently applied.
Strengths of our study are a large cohort of patients
who were consistently treated during a given period, long
follow up, and pathology reviewed at a single institution.
An additional strength is that the method of propensity
scores was used to reduce bias in this retrospective study
design. When a matched analysis was conducted as a sen-
sitivity test to reduce bias using the propensity score, the
results showed that a benefit still existed to the addition of
ADT while controlling for other prognostic factors. The
major limitations in our study are apparent in the non-
randomized nature of patients receiving and not receiving
ADT. This bias is seen in the discrepancy in baseline PSA
values, Gleason scores, and t-stage, and efforts were made
to minimize the bias by use of the propensity score. How-
ever, some of the imbalances seen favored patients that
did not receive ADT, i.e., lower Gleason score and lower
PSA. Despite this, patients who did not receive ADT had
increased biochemical failures. As such, it is likely that
ADT does have a significant biologic effect in reduction of
biochemical failures. In our study, the duration and type
of ADT usage was typical for the time period but not stan-
dardized. Additionally, this retrospective study analysis in-
cluded only patients treated in a tertiary cancer center,
Ludwig et al. BMC Cancer  (2015) 15:190 Page 8 of 8and comorbidities and obesity were not at the time in-
cluded in the data elements, all of which may limit the
generalizability.
An overall improvement in PSA recurrence-free survival
and distant metastasis-free survival was associated with
the use of ADT while controlling for age, T-stage, PSA,
year of diagnosis, and Gleason scores in intermediate risk
prostate cancer. There was no apparent reduction in bio-
chemical failure by giving longer than 6 months duration
of ADT. Randomized trials are in progress to further de-
fine the benefit of androgen deprivation therapy with high
dose external beam radiation in intermediate risk disease.
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